Global Influenza A Virus, H3N2 Subtype Infections Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
The global Influenza A Virus, H3N2 Subtype Infections Drug market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Influenza A Virus, H3N2 Subtype Infections Drug is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Influenza A Virus, H3N2 Subtype Infections Drug is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Influenza A Virus, H3N2 Subtype Infections Drug is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug include AbbVie Inc, AIMM Therapeutics B.V., Aphios Corporation, Celltrion, Inc., FluGen, Inc., Glide Pharmaceutical Technologies Limited, ILiAD Biotechnologies, LLC, Inovio Pharmaceuticals, Inc. and Johnson & Johnson, etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Influenza A Virus, H3N2 Subtype Infections Drug, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Influenza A Virus, H3N2 Subtype Infections Drug by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Influenza A Virus, H3N2 Subtype Infections Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Influenza A Virus, H3N2 Subtype Infections Drug market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
By Company
AbbVie Inc
AIMM Therapeutics B.V.
Aphios Corporation
Celltrion, Inc.
FluGen, Inc.
Glide Pharmaceutical Technologies Limited
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Medicago Inc.
MedImmune, LLC
Mucosis B.V.
NanoViricides, Inc.
OPKO Health, Inc.
Sarepta Therapeutics, Inc.
VBI Vaccines Inc.
Visterra, Inc.
Zydus Cadila Healthcare Limited
By Type
NEO-8877
NP-025
NSC-61610
NVINF-1
Others
By Application
Clinic
Hospital
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Influenza A Virus, H3N2 Subtype Infections Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Influenza A Virus, H3N2 Subtype Infections Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Influenza A Virus, H3N2 Subtype Infections Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
Table of Content
1 Report Overview
1.1 Influenza A Virus, H3N2 Subtype Infections Drug Definition
1.2 Market by Type
1.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 NEO-8877
1.2.3 NP-025
1.2.4 NSC-61610
1.2.5 NVINF-1
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales
2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region
2.3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2018-2023)
2.3.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2024-2034)
2.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Region
2.6.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Manufacturers
3.1.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Influenza A Virus, H3N2 Subtype Infections Drug Sales in 2024
3.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Manufacturers
3.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Influenza A Virus, H3N2 Subtype Infections Drug Revenue in 2024
3.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Manufacturers
3.4 Global Key Players of Influenza A Virus, H3N2 Subtype Infections Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug, Product Offered and Application
3.8 Global Key Manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type
4.1.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type
4.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2018-2034)
4.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Type
4.3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2018-2023)
4.3.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application
5.1.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application
5.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2018-2034)
5.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Application
5.3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2018-2023)
5.3.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Company
6.1.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023)
6.1.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023)
6.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
6.2.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2034)
6.3 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
6.3.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2034)
6.4 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
6.4.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country (2018-2034)
6.4.3 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Company
7.1.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023)
7.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
7.2.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2034)
7.3 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
7.3.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2034)
7.4 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
7.4.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country (2018-2034)
7.4.3 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Influenza A Virus, H3N2 Subtype Infections Drug Sales by Company
8.1.1 China Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023)
8.1.2 China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023)
8.2 China Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
8.2.1 China Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2034)
8.2.2 China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2034)
8.3 China Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
8.3.1 China Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2034)
8.3.2 China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales by Company
9.1.1 APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023)
9.2 APAC Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
9.2.1 APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2034)
9.3 APAC Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
9.3.1 APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2034)
9.4 APAC Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Region
9.4.1 APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2018-2034)
9.4.3 APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 AbbVie Inc
11.1.1 AbbVie Inc Company Information
11.1.2 AbbVie Inc Overview
11.1.3 AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.1.5 AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.1.6 AbbVie Inc Recent Developments
11.2 AIMM Therapeutics B.V.
11.2.1 AIMM Therapeutics B.V. Company Information
11.2.2 AIMM Therapeutics B.V. Overview
11.2.3 AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.2.5 AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.2.6 AIMM Therapeutics B.V. Recent Developments
11.3 Aphios Corporation
11.3.1 Aphios Corporation Company Information
11.3.2 Aphios Corporation Overview
11.3.3 Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.3.5 Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.3.6 Aphios Corporation Recent Developments
11.4 Celltrion, Inc.
11.4.1 Celltrion, Inc. Company Information
11.4.2 Celltrion, Inc. Overview
11.4.3 Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.4.5 Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.4.6 Celltrion, Inc. Recent Developments
11.5 FluGen, Inc.
11.5.1 FluGen, Inc. Company Information
11.5.2 FluGen, Inc. Overview
11.5.3 FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.5.5 FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.5.6 FluGen, Inc. Recent Developments
11.6 Glide Pharmaceutical Technologies Limited
11.6.1 Glide Pharmaceutical Technologies Limited Company Information
11.6.2 Glide Pharmaceutical Technologies Limited Overview
11.6.3 Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.6.5 Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.6.6 Glide Pharmaceutical Technologies Limited Recent Developments
11.7 ILiAD Biotechnologies, LLC
11.7.1 ILiAD Biotechnologies, LLC Company Information
11.7.2 ILiAD Biotechnologies, LLC Overview
11.7.3 ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.7.5 ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.7.6 ILiAD Biotechnologies, LLC Recent Developments
11.8 Inovio Pharmaceuticals, Inc.
11.8.1 Inovio Pharmaceuticals, Inc. Company Information
11.8.2 Inovio Pharmaceuticals, Inc. Overview
11.8.3 Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.8.5 Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.8.6 Inovio Pharmaceuticals, Inc. Recent Developments
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Information
11.9.2 Johnson & Johnson Overview
11.9.3 Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.9.5 Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.9.6 Johnson & Johnson Recent Developments
11.10 Medicago Inc.
11.10.1 Medicago Inc. Company Information
11.10.2 Medicago Inc. Overview
11.10.3 Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.10.5 Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
11.10.6 Medicago Inc. Recent Developments
11.11 MedImmune, LLC
11.11.1 MedImmune, LLC Company Information
11.11.2 MedImmune, LLC Overview
11.11.3 MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.11.5 MedImmune, LLC Recent Developments
11.12 Mucosis B.V.
11.12.1 Mucosis B.V. Company Information
11.12.2 Mucosis B.V. Overview
11.12.3 Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.12.5 Mucosis B.V. Recent Developments
11.13 NanoViricides, Inc.
11.13.1 NanoViricides, Inc. Company Information
11.13.2 NanoViricides, Inc. Overview
11.13.3 NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.13.5 NanoViricides, Inc. Recent Developments
11.14 OPKO Health, Inc.
11.14.1 OPKO Health, Inc. Company Information
11.14.2 OPKO Health, Inc. Overview
11.14.3 OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.14.5 OPKO Health, Inc. Recent Developments
11.15 Sarepta Therapeutics, Inc.
11.15.1 Sarepta Therapeutics, Inc. Company Information
11.15.2 Sarepta Therapeutics, Inc. Overview
11.15.3 Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.15.5 Sarepta Therapeutics, Inc. Recent Developments
11.16 VBI Vaccines Inc.
11.16.1 VBI Vaccines Inc. Company Information
11.16.2 VBI Vaccines Inc. Overview
11.16.3 VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.16.4 VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.16.5 VBI Vaccines Inc. Recent Developments
11.17 Visterra, Inc.
11.17.1 Visterra, Inc. Company Information
11.17.2 Visterra, Inc. Overview
11.17.3 Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.17.4 Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.17.5 Visterra, Inc. Recent Developments
11.18 Zydus Cadila Healthcare Limited
11.18.1 Zydus Cadila Healthcare Limited Company Information
11.18.2 Zydus Cadila Healthcare Limited Overview
11.18.3 Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.18.4 Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Products and Services
11.18.5 Zydus Cadila Healthcare Limited Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Influenza A Virus, H3N2 Subtype Infections Drug Value Chain Analysis
12.2 Influenza A Virus, H3N2 Subtype Infections Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Influenza A Virus, H3N2 Subtype Infections Drug Production Mode & Process
12.4 Influenza A Virus, H3N2 Subtype Infections Drug Sales and Marketing
12.4.1 Influenza A Virus, H3N2 Subtype Infections Drug Sales Channels
12.4.2 Influenza A Virus, H3N2 Subtype Infections Drug Distributors
12.5 Influenza A Virus, H3N2 Subtype Infections Drug Customers
13 Market Dynamics
13.1 Influenza A Virus, H3N2 Subtype Infections Drug Industry Trends
13.2 Influenza A Virus, H3N2 Subtype Infections Drug Market Drivers
13.3 Influenza A Virus, H3N2 Subtype Infections Drug Market Challenges
13.4 Influenza A Virus, H3N2 Subtype Infections Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Figure
List of Tables
Table 1. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of NEO-8877
Table 3. Major Manufacturers of NP-025
Table 4. Major Manufacturers of NSC-61610
Table 5. Major Manufacturers of NVINF-1
Table 6. Major Manufacturers of Others
Table 7. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region (2018-2023)
Table 11. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region (2024-2034)
Table 13. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 14. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2018-2023) & (K Pcs)
Table 15. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Region (2018-2023)
Table 16. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2024-2034) & (K Pcs)
Table 17. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Region (2024-2034)
Table 18. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 19. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 20. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 21. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Manufacturers (2018-2023)
Table 22. Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 23. Global Key Players of Influenza A Virus, H3N2 Subtype Infections Drug, Industry Ranking, 2021 VS 2024
Table 24. Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Influenza A Virus, H3N2 Subtype Infections Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenza A Virus, H3N2 Subtype Infections Drug as of 2024)
Table 26. Global Key Manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug, Product Offered and Application
Table 28. Global Key Manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 31. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 32. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Share by Type (2018-2023)
Table 33. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Share by Type (2024-2034)
Table 34. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 35. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Type (2018-2023)
Table 37. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Type (2024-2034)
Table 38. Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2018-2023) & (USD/Pcs)
Table 39. Global Influenza A Virus, H3N2 Subtype Infections Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 40. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 41. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 42. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Share by Application (2018-2023)
Table 43. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Share by Application (2024-2034)
Table 44. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 45. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Application (2018-2023)
Table 47. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Application (2024-2034)
Table 48. Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2018-2023) & (USD/Pcs)
Table 49. Global Influenza A Virus, H3N2 Subtype Infections Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 50. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 51. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 52. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 53. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 54. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 55. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 57. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 58. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 59. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 61. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country (2018-2023) & (US$ Million)
Table 62. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 64. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 65. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 66. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 67. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 68. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 69. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 70. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 72. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 73. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 74. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 76. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country (2018-2023) & (US$ Million)
Table 77. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 79. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 80. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 81. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 82. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 83. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 84. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 85. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 87. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 88. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 89. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 91. APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 92. APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 93. APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 94. APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 95. APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 97. APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 98. APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 99. APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 101. APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2018-2023) & (US$ Million)
Table 102. APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 104. APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 105. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 106. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Company (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 108. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 109. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2018-2023) & (US$ Million)
Table 110. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 112. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 113. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country (2018-2023) & (US$ Million)
Table 117. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 119. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 120. AbbVie Inc Company Information
Table 121. AbbVie Inc Description and Overview
Table 122. AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 123. AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 124. AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 125. AbbVie Inc Recent Developments
Table 126. AIMM Therapeutics B.V. Company Information
Table 127. AIMM Therapeutics B.V. Description and Overview
Table 128. AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 129. AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 130. AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 131. AIMM Therapeutics B.V. Recent Developments
Table 132. Aphios Corporation Company Information
Table 133. Aphios Corporation Description and Overview
Table 134. Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 135. Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 136. Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 137. Aphios Corporation Recent Developments
Table 138. Celltrion, Inc. Company Information
Table 139. Celltrion, Inc. Description and Overview
Table 140. Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 141. Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 142. Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 143. Celltrion, Inc. Recent Developments
Table 144. FluGen, Inc. Company Information
Table 145. FluGen, Inc. Description and Overview
Table 146. FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 147. FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 148. FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 149. FluGen, Inc. Recent Developments
Table 150. Glide Pharmaceutical Technologies Limited Company Information
Table 151. Glide Pharmaceutical Technologies Limited Description and Overview
Table 152. Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 153. Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 154. Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 155. Glide Pharmaceutical Technologies Limited Recent Developments
Table 156. ILiAD Biotechnologies, LLC Company Information
Table 157. ILiAD Biotechnologies, LLC Description and Overview
Table 158. ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 159. ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 160. ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 161. ILiAD Biotechnologies, LLC Recent Developments
Table 162. Inovio Pharmaceuticals, Inc. Company Information
Table 163. Inovio Pharmaceuticals, Inc. Description and Overview
Table 164. Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 165. Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 166. Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 167. Inovio Pharmaceuticals, Inc. Recent Developments
Table 168. Johnson & Johnson Company Information
Table 169. Johnson & Johnson Description and Overview
Table 170. Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 171. Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 172. Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 173. Johnson & Johnson Recent Developments
Table 174. Medicago Inc. Company Information
Table 175. Medicago Inc. Description and Overview
Table 176. Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 177. Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 178. Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug SWOT Analysis
Table 179. Medicago Inc. Recent Developments
Table 180. MedImmune, LLC Company Information
Table 181. MedImmune, LLC Description and Overview
Table 182. MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 183. MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 184. MedImmune, LLC Recent Developments
Table 185. Mucosis B.V. Company Information
Table 186. Mucosis B.V. Description and Overview
Table 187. Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 188. Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 189. Mucosis B.V. Recent Developments
Table 190. NanoViricides, Inc. Company Information
Table 191. NanoViricides, Inc. Description and Overview
Table 192. NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 193. NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 194. NanoViricides, Inc. Recent Developments
Table 195. OPKO Health, Inc. Company Information
Table 196. OPKO Health, Inc. Description and Overview
Table 197. OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 198. OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 199. OPKO Health, Inc. Recent Developments
Table 200. Sarepta Therapeutics, Inc. Company Information
Table 201. Sarepta Therapeutics, Inc. Description and Overview
Table 202. Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 203. Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 204. Sarepta Therapeutics, Inc. Recent Developments
Table 205. VBI Vaccines Inc. Company Information
Table 206. VBI Vaccines Inc. Description and Overview
Table 207. VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 208. VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 209. VBI Vaccines Inc. Recent Developments
Table 210. Visterra, Inc. Company Information
Table 211. Visterra, Inc. Description and Overview
Table 212. Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 213. Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 214. Visterra, Inc. Recent Developments
Table 215. Zydus Cadila Healthcare Limited Company Information
Table 216. Zydus Cadila Healthcare Limited Description and Overview
Table 217. Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 218. Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Product and Services
Table 219. Zydus Cadila Healthcare Limited Recent Developments
Table 220. Key Raw Materials Lists
Table 221. Raw Materials Key Suppliers Lists
Table 222. Influenza A Virus, H3N2 Subtype Infections Drug Distributors List
Table 223. Influenza A Virus, H3N2 Subtype Infections Drug Customers List
Table 224. Influenza A Virus, H3N2 Subtype Infections Drug Market Trends
Table 225. Influenza A Virus, H3N2 Subtype Infections Drug Market Drivers
Table 226. Influenza A Virus, H3N2 Subtype Infections Drug Market Challenges
Table 227. Influenza A Virus, H3N2 Subtype Infections Drug Market Restraints
Table 228. Research Programs/Design for This Report
Table 229. Key Data Information from Secondary Sources
Table 230. Key Data Information from Primary Sources
List of Figures
Figure 1. Influenza A Virus, H3N2 Subtype Infections Drug Product Picture
Figure 2. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Type in 2024 & 2034
Figure 4. NEO-8877 Product Picture
Figure 5. NP-025 Product Picture
Figure 6. NSC-61610 Product Picture
Figure 7. NVINF-1 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 10. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Application in 2024 & 2034
Figure 11. Clinic
Figure 12. Hospital
Figure 13. Others
Figure 14. Influenza A Virus, H3N2 Subtype Infections Drug Report Years Considered
Figure 15. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 16. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue 2018-2034 (US$ Million)
Figure 17. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 18. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity 2018-2034 (K Pcs)
Figure 19. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Region (2018-2023)
Figure 20. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 22. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 24. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 26. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 28. APAC Influenza A Virus, H3N2 Subtype Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 30. Middle East, Africa and Latin America Influenza A Virus, H3N2 Subtype Infections Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity in 2024
Figure 32. The Top 10 and Top 5 Players Market Share by Influenza A Virus, H3N2 Subtype Infections Drug Revenue in 2024
Figure 33. Influenza A Virus, H3N2 Subtype Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 34. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2018-2034)
Figure 36. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2018-2034)
Figure 38. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Company in 2024
Figure 39. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Company in 2024
Figure 40. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2018-2034)
Figure 42. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2018-2034)
Figure 44. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country (2018-2034)
Figure 45. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Company in 2024
Figure 49. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Company in 2024
Figure 50. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2018-2034)
Figure 52. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2018-2034)
Figure 54. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country (2018-2034)
Figure 55. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 57. France Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Italy Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Russia Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2018-2034) & (US$ Million)
Figure 61. China Influenza A
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices